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Kinetics, dynamics, and bioavailability of 
bumetanide in healthy subjects and 
patients with congestive heart failure 
Four healthy subjects and six patients with congestive heart failure (CHF) were given 3 mg oral and 
intravenous doses of bumetanide in a random crossover fashion. Bumetanide was analyzed by HPLC, 
and sodium and potassium was analyzed by flame photometry. Aside from a modest reduction in renal 
clearance, the kinetics of bumetanide in CHF were similar to those in healthy subjects. The extent of 
bioavailability was 81%, with a variability of 20% to 25% about the mean for both groups. The cumulative 
dynamic responses to bumetanide, whether administered orally or intravenously, were essentially the same 
in each group. Pharmacodynamic modeling showed that there were no significant differences between 
healthy subjects and patients with CHF in either ER. (bumetanide urinary excretion rate producing 50% 
of maximum drug effect) or S (slope), although the baseline effect was 15 times lower in CHF. The 
maximum effect attributable to bumetanide was twofold higher in healthy subjects and there was a 
significant correlation between this parameter and creatinine clearance (r = 0.964; p < 0.001). Overall, 
these results indicate that a predictable transition from 3 mg intravenous to oral doses of bumetanide is 
possible in CHF. (CLAN PHARMACOL THER 1988;44:487-500.) 
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Bumetanide is a loop diuretic similar to furosemide 
with respect to its pharmacologic action and clinical 
indications. It differs from furosemide in that it is 40 
times more potent on a milligram-per-milligram 
Bumetanide is highly protein bound' and rela- 
tively little drug undergoes glomerular filtration. How- 
ever, bumetanide is actively secreted by the pars recta 
of the proximal tubule.' This is important because 
numerous investigators have shown that bumetanide 
exerts its primary natriuretic action on the thick as- 
cending limb of Henle from the luminal side.' As a 
result, any pathophysiologic condition that affects the 
tubular secretion of bumetanide may attenuate the drug- 
induced pharmacologic effect. 
The pharmacokinetics of drugs may be affected by 
cardiac disease." Studies comparing healthy subjects 
with patients with congestive heart failure (CHF) have 
reported that changes in the bioavailability, volume of 
distribution, or clearance of drugs may occur in heart 
failure. Many investigators have focused on reduced 
drug clearance in CHF, which may be due to diminished 
blood flow to the kidney or liver or to compromised 
enzyme activity secondary to hepatic congestion. 1' 
However, very few studies have been completed that 
examine the effects of CHF on the bioavailability of 
compounds with low hepatic extraction, although al- 
terations in absorption could result from changes in 
autonomic nervous activity, blood flow to the mesen- 
teric area, or gut wall edema associated with cardiac 
congestion. 
Both bumetanide and furosemide are used in the 
treatment of edema associated with CHF."' However, 
the pharmacodynamics of furosemide are variable, and 
suboptimal responses can occur, especially after oral 
dosing.'" These problems may be due, in part, to the 
incomplete and unpredictable bioavailability of furo- 
semide.""-" In contrast, bumetanide has consistently 
high bioavailability in healthy subjects"°-"-" and in pa- 
tients with hepatic or renal diseases.628 Nevertheless, 
pharmacokinetic and pharmacodynamic data for bumet- 
anide in CHF are very limited.' Therefore, we under- 
took a study to determine the pharmacokinetics, phar- 
macodynamics, and bioavailability of bumetanide in 
patients with severe CHF after both oral and intravenous 
dosing. Parallel studies were carried out in healthy sub- 
jects for the purpose of comparison. 
METHODS 
Materials. Bumetanide tablets (1 mg; lot 0303-1) and 
intravenous solution (0.25 mg / ml; lot 3003) were ob- 
tained from Hoffmann-La Roche, Inc., Nutley, N.J. 
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All other chemicals and solvents were reagent grade or 
better, as previously reported.3° 
Study participants. This study was performed in the 
Clinical Research Center and the University of Mich- 
igan Hospitals. The control group consisted of four 
healthy subjects as judged by medical history, physical 
examination, and standard laboratory test results, in- 
cluding a creatinine clearance (CLcR) determination 
(Table I). The group of patients with CHF consisted of 
six individuals with class III or IV heart failure, ac- 
cording to the New York Heart Association criteria for 
functional capacity.' CL,R in these patients was stable 
at _ -35 ml/ min (Table I). Patients must have been re- 
ceiving a daily maintenance dose of 80 to 240 mg of 
furosemide as part of their prescribed drug therapy to 
be eligible for study. Patients were excluded from study 
if they had diabetes or signs and symptoms of hema- 
tologic, gastrointestinal, or hepatic diseases other than 
hepatic dysfunction associated with CHF. Patients re- 
ceiving long-acting diuretics (i.e., metolazone, spi- 
ronolactone) were also excluded from study. All di- 
uretics were withheld for 24 hours before each study 
day, and drugs that have diuretic-like properties 
(i.e. , theophylline) or that may inhibit the diuretic re- 
sponses (i.e., nonsteroidal antiinflammatory drugs) 
were not allowed for a minimum of 3 days before 
bumetanide administration (except for patient 6, who 
was taking one aspirin tablet per day). Each volunteer 
was instructed to avoid caffeine-containing beverages 
throughout the study. All participants were fully in- 
formed of the nature of the study and signed an informed 
consent form approved by the Committee to Review 
Grants for Clinical Research and Investigation Involv- 
ing Human Beings of the University of Michigan Med- 
ical Center. 
Study design. After an overnight fast, each patient 
received a 3 mg dose of bumetanide, either orally (three 
tablets) or intravenously, at 8 AM in a random crossover 
design. There was a minimum of at least 2 days between 
the two treatments. Bumetanide tablets were taken with 
8 oz of water; the solution was infused at a constant 
rate over 3 minutes. For the intravenous dose, serial 
blood samples (3 ml) were drawn from the contralateral 
arm through an indwelling heparinized (10 U/ ml) scalp 
vein needle into tubes containing EDTA just before 
bumetanide dosing (blank) and at 3, 5, 10, 20, 30, 45, 
60, 90, 120, 150, 180, 240, 300, 360, 480, and 1440 
minutes after the start of the infusion. For the oral dose, 
serial blood samples were drawn just before dosing 
(blank) and at 15, 30, 45, 60, 90, 120, 150, 180, 240, 
300, 360, 420, 480, and 1440 minutes after drug dos- 
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Table I. Clinical data of healthy subjects and patients with CHF 
LVEF, left ventricular ejection fraction. 
*Determined over 24 hours. 
ing. Blood samples were centrifuged immediately and 
the plasma was harvested and frozen. Voided urine 
was collected just before bumetanide administration 
(blank), every half hour for the first 3 hours, hourly for 
the next 5 hours, and then pooled from 8 to 24 hours 
after drug dosing. Plasma and urine samples were stored 
at 20° C until subsequent analysis. 
Healthy subjects were kept relatively euvolemic 
throughout the study by replacing urinary losses iso- 
volumetrically; 75% was replaced with intravenous ad- 
ministration of lactated Ringer's solution and the re- 
maining 25% was replaced orally with water. Patients 
were allowed water and fruit juices throughout the study 
according to their prescribed fluid and dietary restric- 
tions (i.e., a no-added-salt diet before and during 
study). A low-sodium lunch (30 to 50 mEq) was pro- 
vided for each participant 4 hours after dosing. All 
plasma samples in healthy subjects and patients showed 
normal sodium concentrations. 
Analytic procedures. Plasma and urine samples con- 
taining bumetanide were analyzed by a sensitive and 
specific HPLC assay.3° Plasma and urine samples were 
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assayed for sodium and potassium with a flame pho- 
tometer (Model 455, Corning Medical and Scientific, 
Medfield, Mass.). 
Protein binding. The plasma protein binding of 
bumetanide was determined for each participant by 
spiking the pooled plasma samples with bumetanide 
over a concentration range of 5 to 50 lig / ml. The con- 
centration of bumetanide in the original samples was 
<2% of the spiked concentrations. Plasma (0.5 ml) 
was dialyzed against an equal volume of isotonic phos- 
phate buffer (0.067 mol/ L at pH 7.4) at 37° C for 5 
hours. Dialysis membranes with a molecular weight 
cutoff of 12,000 to 14,000 daltons and 1 ml dialysis 
cells were used throughout. Preliminary studies indi- 
cated that equilibrium was achieved within 2 hours and 
was maintained for 24 hours. Spiked plasma (0.2 ml) 
was prepared and analyzed as previously reported." 
Dialyzed buffer (0.2 ml) was mixed with 50 RI ace- 
tophenone (0.25 mg / ml) and injected into the HPLC 
system, as reported previously.' A typical standard 
curve of bumetanide/ acetophenone peak height ratio 









(m11 min) Concomitant drugs 
Healthy subjects 
1 34 68.1 125 
2 25 73.1 117 
3 38 68.1 108 
4 23 66.1 121 
Mean 30 68.9 118 
SD 7 3.0 7 
Patients with CHF 
1 70 62.7 14 35 Digoxin, captopril, potassium 
chloride 
2 38 84.5 21 65 Digoxin, captopril, docusate 
sodium, quinidine, diphen- 
hydramine 
3 57 82.8 28 45 Captopril, ferrous sulfate, do- 
cusate sodium, potassium 
chloride 
4 63 59.2 10 37 Digoxin, captopril, hydral- 
azine, warfarin, allopurinol 
5 61 53.2 15 55 Digoxin, captopril, potassium 
chloride, isosorbide dini- 
trate, imazodan 
6 71 62.2 30 35 Amiodarone, enalapril, potas- 
sium chloride, isosorbide 
dinitrate, aspirin 
Mean 60 67.4 20 45 
SD 12 13.0 8 12 
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to 206 ng/ ml resulted in the linear least-squares regres- 
sion equation: 1.502X 0.018 (r2 = 0.999). The 
volume-corrected bound concentration after dialysis 
(Cb") was calculated as: Cb" = CT 2Cf' , where CT 
is the measured total concentration of drug in plasma 
before dialysis and Cf' represents the measured un- 
bound concentration of drug in the buffer after dialysis. 
This equation was developed by Tozer et al.' to correct 
for the osmotic water shift that occurs during equilib- 
rium dialysis, resulting in lower protein and bound drug 
concentrations in the postdialysis plasma compartment. 
The appropriate bound and free concentrations were 
then fit with MKMODEL' to a nonlinear plasma pro- 
tein binding model: 
Cb" = PI x Cf'/(P2 + Cf') (1) 
where P1 represents the maximum binding capacity of 
the plasma proteins and P2 is the Cr concentration that 
produces one half the maximum binding capacity. Other 
binding models were also tested (linear, one Langmuir 
plus a linear term, and two Langmuirs). However, the 
data were best described by Eq. 1, as judged by the 
Schwarz criterion' and by visual examination of the 
residuals. 
Kinetics. Noninstantaneous mixing of drug in the 
sampling compartment was observed during the intra- 
venous infusion of bumetanide. This resulted in peak 
plasma concentrations of bumetanide at times after the 
end of infusion. Therefore, plasma concentration-time 
curves of bumetanide after intravenous infusions were 
fit to the following general polyexponential equation: 
C = Ro/V, E (1 ex T) e-x; - tlagiv) (2) 
= I 
IT (E, ki)/[ X, IT (Xk X)] 
k = 2 k = 1 
k * i 
where C is the plasma concentration of bumetanide at 
time t, Ro is the rate of bumetanide infusion, V, is the 
volume of the central compartment, n is the number of 
exponents, Xi is the exponent of the ith exponential 
term, T is the infusion time, tlag, is the time lag be- 
tween the beginning of the infusion and the appearance 
of bumetanide in the sampling compartment, and Ek is 
the sum of the exit rate constants from the kth com- 
partment. Parameter estimates were obtained by the use 
of the nonlinear least-squares regression program 
MKMODEL." The number of exponents needed for 
each data set was determined by the application of 
Schwarz criterion,' ensuring that the coefficients of the 
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corresponding bolus dose equation were all positive, 
and by visual examination of the residuals. Once the 
regression parameters were obtained, the coefficients 
(Ci) of the corresponding bolus dose equation could be 
calculated as follows": 
C, = D/V, IT (E, Xi)/ IT (X, - (3) 
k = 2 k = 1 
k * i 
where D is the total dose administered (Ro T). 
The following pharmacokinetic parameters were then 
calculated from standard equations"' 
In Eqs. 4 to 10, Vs, is the volume of distribution steady 
state; Vaa is that volume which, when multiplied by 
C in the log-linear phase, is equal to the amount of drug 
in the body; CL is the total plasma clearance; CL, is 
the renal clearance; CL, is the nonrenal clearance; 
Ae(0 cc) is the amount of unchanged drug recovered 
in the urine at time infinity; ti is the biologic half-life; 
X. is the smallest of the X, values; and F, is the fraction 
of the dose excreted unchanged in the urine. 
Plasma concentration-time profiles of oral bumet- 
anide were not computer fit because of irregular ab- 
sorption profiles in many of the participants. Pertinent 
kinetic parameters were therefore calculated by a non- 
compartmental approach. The biologic t112 with oral dos- 
ing (t112p.) was graphically determined by linear regres- 
sion of In(C) vs. time with use of at least three data 
points from the log-linear terminal phase. CL, was de- 
termined by division of Ae(0 cc) by the plasma 
AUC(0 cc), calculated by a combination of the trap- 
ezoidal and log-trapezoidal rules and extrapolated to 
infinity as C1.1 ti,20/ 0.693. The peak plasma concen- 
tration (Cm.) and time to peak (tmax) after an oral dose 
were read directly from the plasma concentration-time 
curve. 
Bioavailability. The extent of systemic availability 
V = D E C,A.,2/RE CA,)21 (4) 
= D/(X, E C,/X,) (5) 
CL = D/ E C,/ X, 
i = I 
(6) 
CL, = Ae(0-00)/ E C,/X; (7) 
CLNR = CL CLR (8) 
t,,, = 0.693/X, (9) 
Fe = Ae(0 00)/D (10) 
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of bumetanide was calculated by the area ratios of oral 
(po) and intravenous (iv) dosing: 
Fp = AUC(0 - 00),/ AUC(0 - CO)., (11) 
by urinary excretion ratios: 
Fp = Ae(0 - 00),/ Ae(0 - G°),, (12) 
and by correction for differences in CLR between oral 
and intravenous doses as suggested by Oie and 
Jung." 
Fco, = - Ae(0 - co),,)AUC(0 - x),./ (13) 
AUC(0 - Ae(0 - 09), ji Dpo 
For the calculations of Fp and Feo,,, AUC(0 - 00)o, was 
determined by a combination of the trapezoidal and log- 
trapezoidal rules, extrapolated to infinity by Clast 
t1/2,10.693. The ti/2, was graphically determined by 
linear regression with use of at least four data points 
from the log-linear terminal phase. The computer-fitted 
and noncompartmental estimates of AUC(0 - 09,, dif- 
fered from one another by <7%. These small deviations 
were probably due to differences between the computer 
fit and graphically determined estimates of t1,2, and the 
overestimation of AUC by the noncompartmental 
method during the period of noninstantaneous mixing 
of drug in the sampling compartment. 
The mean absorption time (MAT) was used as a mea- 
sure of the absorption rate of oral bumetanide according 
to the noncompartmental method of statistical mo- 
ments.38.39 MAT was calculated as the difference of 
mean residence times (MRTs) between oral and intra- 
venous dosing as: 
MAT = MRT, - MRT, (14) 
where MRT equals the area under the first moment 
curve (AUMC; extrapolated to infinity) divided by 
AUC(0 - 00). The AUMC was estimated by a com- 
bination of the trapezoidal and log-trapezoidal rules, 
extrapolated to infinity by tiast Clast t1/2/0.693 + CI. 
(t11210.693)3. An MAT value that corrects for the time 
lag (tlagpo) before drug absorption was also calculated: 
MAT_ = MAT - flag, (15) 
The flag,0 was estimated from absorption profiles by 
use of the exact Loo-Riegelman equation of Wagner' 
and the second derivative criterion of Proost" for eval- 
uation of the two integrals of that equation. 
Dynamics. The relationship between the sodium ex- 
cretion rate (E; in milliequivalents per minute) and the 
urinary excretion rate of bumetanide (ER; in micro- 
Table IL Binding parameters for bumetanide in 
healthy subjects and patients with CHF 
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grams per minute) was evaluated by use of the sigmoid 
Emax model:' 
E = Em,, ERs/(ER50' + ER') + Eo (16) 
where Eroax is the maximum effect attributable to the 
drug, ER50 is the urinary excretion rate of bumetanide 
that produces 50% of the Eroax, Eo is the baseline effect, 
and S is the parameter influencing the slope of the dose- 
effect curve. The unknown parameters (Erna., ER50, 
Eo, and S) were determined after intravenous dosing 
of bumetanide for each individual by use of the 
MKMODEL program.33 
Phannacodynamic data were also reported as the 8- 
hour cumulative excretion of sodium and the overall 
efficiency (Eff ) of the response: 
Eff = (AE - AE0)/AAe (17) 
where AE and AAe are the amount of sodium and drug 
excreted in urine, respectively, over the same 8-hour 
period. AEo was estimated by multiplying the computer- 
fitted value for baseline effect, E0, by 240 minutes. 
Statistics. Unless otherwise indicated, data are ex- 
pressed as the mean ± SD. Statistical differences be- 
tween the healthy subjects and the patients with CHF 
were determined by one-way ANOVA. Statistical dif- 
ferences between oral and intravenous dosing within 




( jug 1 ml) (%) 
Healthy subjects 
1 343 ± 179 4.85 ± 2.87 1.40 
2 428 ± 87 4.12 ± 0.96 0.95 
3 112 ± 16 0.87 ± 0.20 0.77 
4 421 ± 144 5.52 ± 2.11 1.30 
Mean 326 3.84 1.11 
SD 148 2.06 0.30 
Patients with CHF 
1 235 ± 45 3.85 ± 0.88 1.60 
2 234 ± 108 3.55 ± 1.91 1.49 
3 240 ± 65 2.60 ± 0.88 1.07 
4 244 ± 62 2.71 ± 0.84 1.10 
5 381 ± 314 6.08 ± 5.65 1.57 
6 132 ± 7 1.46 ± 0.11 1.10 
Mean 244 3.38 1.32 
SD 79 1.57 0.26 
Significance NS NS NS 
(p > 0.20) (p > 0.50) (p > 0.20) 
1 
-l (%) 17.6 5.5 18.7 




Fig. 1. Mean ( SE) plasma concentration-time profiles of 
bumetanide in healthy subjects after 3 mg oral () and intra- 
venous (0) doses. 
calculations (1 13) were also performed at the 
a = 0.05 level." The linear relationship between two 
variables was assessed by the correlation coefficient r. 
A p value --50.05 was considered significant. 
The nonlinear regression of the pharmacokinetic and 
pharmacodynamic modeling equations was estimated 
by MKMODEL." This afforded the use of an extended 
least-squares objective function to make the selection 
of the weighting scheme less arbitrary."' The variance 
model used was: 
Var = 1E-8 + YPWR (18) 
where Var is the variance of the predicted Y and PWR 
is the power parameter. This model predicts VAR = 
lE 8 when Y = 0. This was necessary when esti- 
mating lag times because predicted concentrations are 
equal to 0 for times less than tlag. 
RESULTS 
Results of the plasma protein binding fits are pre- 
sented in Table II. Because the P2 values for all par- 
ticipants were >100 times those of unbound drug con- 
centrations in plasma, it was concluded that the ther- 
apeutic concentrations were in the linear portion of the 
10 
lo° 
0 100 200 300 400 500 
Time (min) 
Fig. 2. Mean ( ± SE) plasma concentration-time profiles of 
bumetanide in patients with CHF after 3 mg oral (II) and 
intravenous (0) doses. 
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binding curve. The percent unbound (fu) was thus cal- 
culated as: 
fu = 100/(Pl/P2 + 1) (19) 
There was no statistically significant difference in fu 
between the two groups. 
Semilogarithmic plots of the plasma concentration- 
time curves for intravenous and oral bumetanide are 
shown in Fig. 1 for healthy subjects and in Fig. 2 for 
patients with CHF. In all cases the intravenous infusion 
data were best fit by a biexponential equation (Ta- 
ble III). 
Pharmacokinetic parameters calculated from intra- 
venous bumetanide data are listed in Table IV. No sta- 
tistically significant differences were found among any 
of the reported parameters. There was, however, a trend 
for a longer t1,2 (72.5 ± 29.3 minutes in patients with 
CHF vs. 46.1 ± 10.2 minutes in healthy subjects; 
p = 0.13) and longer flag, (2.93 ± 1.97 minutes in 
patients with CHF vs. 1.44 ± 0.35 minutes in healthy 
subjects; p = 0.18) in patients with CHF when com- 
pared with normal subjects. When data from the only 
participant (patient 3) who failed to show any tlag,, 
200 0 100 300 400 
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Table III. Coefficients and exponential terms of intravenous bumetanide in healthy subjects and patients 
with CHF 
*r2 = I - (Y.b, -ic)2/1, [Yobs - (Yob,/N)12 
Table IV. Pharmacokinetic parameters after intravenous bumetanide in healthy subjects and patients 
with CHF 
were omitted, there was a significant difference in tlag, 
between the two groups (3.51 ± 1.51 minutes in pa- 
tients with CHF vs. 1.44 -± 0.35 minutes in healthy 
subjects; p < 0.05). Due to serial blood sampling dif- 
ficulties, the first two postinfusion plasma samples from 
patient 3 were drawn at 4 and 8 minutes instead of 3 
and 5 minutes, and may have rendered any tlag,,, unob- 
servable. It should be noted that although the number 
of subjects studied is small (n = 4), their kinetic pa- 
rameters are remarkably similar to those reported by 
Lau et al.6 
Kinetic data after oral bumetanide dosing are listed 
in Table V. CL, was significantly reduced in patients 
(1.03 -± 0.46 ml / min /kg in patients with CHF vs. 
1.83 It. 0.38 ml/ min / kg in healthy subjects; 
Bumetanide 493 
p < 0.025). There were no significant differences 
among the other kinetic parameters after oral bumet- 
anide despite the same trend of a longer ti,2 in patients 
(98.7 -± 39.9 minutes in patients with CHF vs. 
59.5 ± 25.0 minutes in healthy subjects; p = 0.12). 
In addition, there were no differences between groups 
in any of the values calculated for extent of systemic 
availability. Although no statistical difference was 
found in the biologic ti,2 in either group as a function 
of the route of administration, CL, was significantly 
different in healthy subjects (p < 0.05). Therefore, the 
F value corrected for changes in CLR (81.3% ± 16.4% 
for patients with CHF vs. 81.3% ± 18.4% for healthy 











criterion" Power r?* 
Healthy subjects 
0.306 1.91E -2 0.607 1.85E - 1 41.5 -1.08 0.999 
2 0.132 1.30E -2 0.421 1.09E - 1 50.5 +0.16 1.000 
3 0.188 1.81E - 2 0.651 1.63E - 1 26.3 +1.25 0.997 
4 0.222 1.23E - 2 0.368 7.56E - 2 47.9 +1.17 0.996 
Mean 0.212 1.56E - 2 0.512 1.33E - 1 
SD 0.073 0.35E - 2 0.138 0.50E - 1 
Patients with CHF 
1 0.211 5.67E - 3 0.519 7.61E - 2 49.2 +0.45 0.999 
2 0.211 1.20E -2 0.288 4.71E - 2 34.9 +1.21 0.998 
3 0.216 7.97E - 3 0.456 5.48E - 2 52.7 -0.16 1.000 
4 0.180 1.86E -2 1.049 4.11E - 1 33.0 -0.74 0.999 
5 0.118 9.77E -3 0.118 1.12E - 1 49.0 -0.07 0.999 
6 0.258 1.16E - 2 0.414 1.12E - 1 47.6 -0.47 0.999 
Mean 0.199 1.09E - 2 0.474 1.36E- 1 





CHF Significance 1 - (%) 
CL (ml/mm/kg) 2.55 ± 0.54 2.22 ± 1.36 NS (p > 0.50) 6.1 
CLR (ml/min/kg) 1.54 -± 0.40 1.23 ± 0.70 NS (p > 0.40) 10.6 
CLNR (ml/min/kg) 1.01 -± 0.56 0.99 -± 0.75 NS (p > 0.50) 2.7 
ti,, (min) 46.1 -± 10.2 72.5 ± 29.3 NS (p >0.10) 33.0 
Vc (ml/kg) 63.3 ± 15.0 70.6 -± 26.4 NS (p > 0.50) 6.4 
(ml/kg) 131 ± 32 164 -± 74 NS (p > 0.40) 11.1 
V a,, (ml/kg) 168 46 201 ± 94 NS (p > 0.50) 8.2 
F, (%) 61.8 -± 19.7 58.2 -± 14.3 NS (p > 0.50) 4.8 
tlag ,, (min) 1.44 ± 0.35 2.93 ± 1.97 NS (p >0.10) 26.1 
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Table V. Absorption and disposition characteristics of oral bumetanide in healthy subjects and patients 
with CHF 
Eff(8 hr), efficiency of response over 8-hour collection period. 
Natriuretic, kaliuretic, and diuretic responses after 
oral and intravenous dosing of bumetanide are listed in 
Table VI. Sodium excretion corrected for drug excretion 
(i.e., efficiency) is also shown in this table. As ob- 
served, bumetanide elicited equivalent pharmacologic 
responses in both healthy subjects and patients with 
CHF with oral or intravenous administration. Results 
from the dynamic modeling are prescribed in Table VII. 
There was a highly significant difference in E,, be- 
tween groups (1.23 .± 0.22 mEq/ min in patients with 
CHF vs. 2.65 ± 0.13 mEq/ min in healthy subjects; 
p < 0.001). Baseline sodium excretion was also 15 
times greater in healthy subjects (0.016 -± 0.015 
mEq / min in patients with CHF vs. 0.252 ± 0.078 
mEq / min in healthy subjects; p < 0.001). There were 
no significant differences in ER50 or S. In fitting the 
data to the sigmoid Ema model, the first collection pe- 
Table VI. Pharmacodynamic characteristics after intravenous and oral doses of bumetanide in healthy 
subjects and patients with CHF 
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nod (value in parenthesis in Figs. 3 and 4) was omitted 
due to an observed counterclockwise hysteresis. This 
hysteresis, which has been reported for bumetanide in 
dogs7'47 and in man," results from a disequilibrium 
that occurs between the urine and effect compartments 
soon after dosing. Dynamic parameters were not eval- 
uated during oral bumetanide dosing, because bumet- 
anide excretion rates were not sufficient to describe all 
of the sigmoidal-shaped curve. Nevertheless, similar 
profiles were observed for the dose-response relation- 
ship of bumetanide when oral and intravenous data were 
superimposed on each other (Figs. 3 and 4). 
DISCUSSION 
Brater et al.' have studied the pharmacokinetics and 
phannacodynamics of bumetanide in CHF after 1 and 
2 mg oral doses. They observed a statistically signifi- 
Parameter Intravenous Oral Significance I 
- (%) 
Healthy subjects 
Na (mEq/8 hr) 451 ± 55 542 ± 99 NS (p > 0.10) 24.2 
Na (mEq/24 lu-) 496 ± 82 624 ± 119 NS (p > 0.10) 25.8 
K (mEq/8 hr) 68.0 ± 8.1 79.0 ± 7.8 NS (p > 0.10) 22.7 
K (mEq/24 hr) 84.6 ± 19.7 105 ± 11 NS (p > 0.05) 58.3 
Urine (m1/8 hr) 4230 ± 900 5180 ± 1060 NS (p > 0.20) 21.2 
Urine (m1/24 hr) 4700 ± 1210 5780 ± 1130 NS (p > 0.20) 17.9 
Eff(8 hr) (mEq/mg) 0.191 ± 0.052 0.267 ± 0.046 NS (p > 0.05) 46.8 
Patients with CHF 
Na (mEq/8 hr) 188 ± 40 164 ± 63 NS (p > 0.40) 11.5 
Na (mEq/24 hr) 204 ± 37 183 ± 73 NS (p > 0.40) 9.3 
K (mEq/8 hr) 54.2 ± 20.6 60.9 ± 22.2 NS (p > 0.20) 21.2 
K (mEq/24 hr) 86.2 ± 34.5 101 ± 43 NS (p > 0.05) 40.5 
Urine (m1/8 hr) 2270 ± 850 2210 ± 570 NS (p > 0.50) 4.5 
Urine (m1/24 hr) 2870 ± 970 3090 ± 1250 NS (p > 0.20) 15.6 





CHF Significance 1 - 13 (%) 
C_ (ng/ml) 106 ± 22 107 ± 42 NS (p >0.50) 2.7 
tma (min) 74.4 ± 23.5 96.4 ± 48.0 NS (p >0.40) 11.3 
flag, (min) 24.8 ± 7.4 20.5 ± 13.0 NS (p >0.50) 6.9 
MAT (min) 62.9 20.0 103 ±- 59 NS (p >0.20) 20.9 
MAT_ (min) 35.9 ± 9.9 82.7 ± 47.5 NS (p >0.10) 34.1 
t1/2 (min) 59.5 ± 25.0 98.7 39.9 NS (p >0.10) 34.1 
CUR (ml/min/kg) 1.83 ± 0.38 1.03 ± 0.46 S (p <0.025) 72.2 
Fp (%) 70.4 ± 17.4 85.1 ± 25.8 NS (p >0.30) 14.2 
Fp (%) 90.4 21.0 77.4 10.4 NS (p >0.20) 21.8 
Pcon. (%) 81.3 ± 18.4 81.3 ± 16.4 NS (p >0.50) 2.5 
y = 1 - - - 
,0.2 10'1 100 101 102 
Bumetanide Excretion Rate (mcg/min) 
Fig. 3. Mean ( ± SE) sodium excretion vs. urinary excretion 
rates of bumetanide in healthy subjects after 3 mg oral () 
and intravenous (0) doses. Solid line represents the computer- 
generated regression line based on the fitted regression pa- 




Table VII. Dose-response parameters in healthy subjects and patients with CHF after 
intravenous bumetanide 
101 
Bumetanide Excretion Rate (mcg/min) 
Fig. 4. Mean ( ± SE) sodium excretion vs. urinary excretion 
rates of bumetanide in patients with CHF after 3 mg oral (N) 
and intravenous (0) doses. Solid line represents the computer- 
generated regression line based on the fitted regression pa- 
rameters in Table VII. 
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(mEq I min) 
Schwarz 
criterion" Power r2* 
Healthy subjects 
1 2.35 1.49 2.69 0.273 8.13 -2.62 0.973 
2 2.62 2.73 3.71 0.306 9.97 -3.02 0.988 
3 2.70 2.17 2.77 0.137 6.57 -0.46 0.994 
4 2.93 1.66 4.68 0.296 6.48 -1.07 0.992 
Mean 2.65 2.01 3.46 0.252 
SD 0.24 0.56 0.93 0.078 
Patients with CHF 
1 1.03 1.28 4.25 1.78E-2 5.70 + 1.86 0.884 
2 1.47 1.76 2.97 7.02E-3 32.5 + 9.24 0.862 
3 1.42 3.66 3.32 9.75E-4 16.1 +2.11 0.960 
4 1.06 2.03 3.72 2.70E-2 5.36 + 1.75 0.970 
5 1.39 1.60 4.04 6.45E-3 10.5 + 1.16 0.979 
6 1.00 2.71 1.58 3.91E-2 16.1 -0.04 0.996 
Mean 1.23 2.17 3.31 1.64E-2 
SD 0.22 0.87 0.97 1.45E-2 
Significance NS NS 
(p <0.001) (p > 0.50) (p > 0.50) (p < 0.001) 
VOLUME 44 
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1 - 13 (%) >99.9 4.1 4.8 >99.9 
Creatinine Clearance (ml/min) 
Fig. 5. Relationship between Ema and CLeR in healthy subjects 
(0) and patients with CHF (). Solid line represents linear 
correlation between these two parameters (r 0.964; 
p < 0.001). 
cant increase in t112 between patients with CHF and 
normal subjects. This trend was also seen in our study 
(Tables IV and V), but the differences were not statis- 
tically significant. Brater et al. suggested that this two- 
fold increase in t172 observed for patients with CHF may 
be due to either a modest decrement in renal function 
or an increase in the volume of distribution, but they 
could not differentiate between the two because intra- 
venous bumetanide was not administered in their study. 
In our study we saw no statistical difference in volumes 
of distribution. However, a substantial reduction (40%) 
in CI., did occur after oral bumetanide administration 
when comparing healthy subjects and patients with CHF 
(1.83 ± 0.38 vs. 1.03 ± 0.46 ml/min/kg, respec- 
tively; p < 0.025). Additionally, a 20% reduction of 
renal clearance in patients with CHF (vs. healthy sub- 
jects) occurred when bumetanide was administered in- 
travenously; this difference was not statistically sig- 
nificant. 
As noted previously, there was a trend for the flag, 
in healthy subjects to be less than that in patients with 
CHF. This could be the result of a decreased cardiac 
output in patients with CHF, in whom the left ventric- 
ular ejection fraction (LVEF) averaged 20%. However, 
no significant correlation was found between LVEF and 
tlag,, in CHF. This may be a result of the limited number 
of patients studied and the narrow range of LVEF values 
observed (10% to 30%). 
The absorption profile of bumetanide in both groups 
was found to be quite variable, with large coefficients 
of variation (35% in healthy subjects and 64% in pa- 
tients) associated with the mean values for MAT,,. In 
addition, a lag time of 20 to 25 minutes was observed 
for both groups. This value is in close agreement to 
values obtained by other authors 6.26,27 When the extent 
of availability was calculated by correcting for differ- 
ences in CL between oral and intravenous treatments 
of bumetanide, 81% bioavailability (Fc0,) was obtained 
for both groups. This value was less than the 89% mean 
bioavailability reported by Marcantonio et al." and 
greater than the 66% mean bioavailability reported by 
Lau et al.6 in healthy subjects, even though similar 
sensitive and specific HPLC assays were used. It is 
conceivable that dose-dependent absorption may be oc- 
curring, as Marcantonio et al." administered a 1 mg 
dose, the present study involved a 3 mg dose, and Lau 
et al. gave a 5 mg dose. Earlier studies by Pentikainen 
et al.' and Halladay et al." reported nearly complete 
absorption (>95%) of bumetanide, but these results are 
suspect because a nonspecific assay that measured drug 
with the total radioactivity in various biologic fluids 
was used. More recently, Holazo et al.' used an RIA 
to investigate the bioavailability of 1 mg doses of 
bumetanide in 12 healthy volunteers. These investi- 
gators reported bioavailabilities of 78% and 86%, de- 
pending on whether plasma data or urine data alone 
were used for calculation, respectively. In other disease 
states, Lau et al. reported a bioavailability of 69% in 
patients with chronic renal failure (5 mg doses) and 
Marcantonio et al.' reported a bioavailability of 83% 
in patients with chronic renal failure and 94% in patients 
with hepatic disease (1 mg doses). 
As summarized in Table VI, bumetanide elicited an 
equivalent natriuresis, kaliuresis, and urine flow in 
healthy subjects and patients with CHF whether ad- 
ministered orally or intravenously. This occurred de- 
spite a 20% decrease in systemic availability when 
bumetanide was administered orally. Although not sta- 
tistically significant, there was a trend for an increase 
in efficiency when both groups took bumetanide 
by mouth (0.267 ± 0.046 [oral] vs. 0.191 ± 0.052 
mEq / / 8 hr [intravenous] for the healthy subjects; 
0.134 ± 0.053 [oral] vs. 0.112 -± 0.029 mEq/fig/8 hr 
[intravenous] for the CHF group); the lack of signifi- 
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Bumetanide Excretion Rate (mcg/min) 
cance may reflect the limited number of study partici- 
pants. Kaojarern et al.' calculated the existence of a 
single maximally efficient excretion rate in the phar- 
macodynamic (sigmoid En,) model. As a result, if the 
drug can remain close to this maximally efficient ex- 
cretion rate for prolonged periods during oral dosing, 
the same or greater cumulative response can occur with 
less total drug reaching the urine. This finding is in 
agreement with the data in our study and may explain 
the equivalency of response between oral and intrave- 
nous administration, despite 20% less drug reaching the 
urine after the oral dose. 
As shown in Table VII, there were no significant 
differences between healthy subjects and patients with 
CHF in either ER50 or S. However, there was a 15- 
fold difference in the baseline sodium excretion rate 
(0.252 ± 0.078 inEq/ min for healthy subjects vs. 
0.016 ± 0.014 mEq / min for patients with CHF; 
p < 0.01). This difference may reflect, in part, the 
fact that patients were eating sodium-restricted diets, 
whereas the healthy subjects were not. In healthy sub- 
jects, urinary sodium losses were also replaced intra- 
venously with lactated Ringer's solution, whereas in 
patients with CHF urine losses were not replaced. The 
Erna, was 50% less in patients with CHF than in healthy 
subjects (2.65 -± 0.24 vs. 1.23 ± 0.22 mEq/ min, re- 
spectively; p <0.001). This may be due to diminished 
filtered sodium as reflected in the reduced CLci, or an 
increased reabsorption of solute in the nephron.'" Fur- 




.001 .01 .1 
Bumetanide Excretion Rate/CLcr (mcg/ml) 
Fig. 6. Dose-response relationships of bumetanide in healthy subjects (D) and in patients with CHF 
(N). Left, dose is expressed as bumetanide excretion rate and response is shown as sodium excretion 
rate. Right, dose is expressed as bumetanide excretion rate corrected for CLc, and response is 
expressed as fractional sodium excretion. 
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Emax and CL,R (Fig. 5;r = 0.964; p <0.001). It there- 
fore seems logical to correct the pharmacodynamic pa- 
rameters for changes in functional nephron mass be- 
tween the two groups. This was accomplished by di- 
viding Emax and Eo by CLcR and by plasma sodium 
concentration; ER 5o was divided by CL,. As shown in 
Fig. 6, a shift to the right is observed for the dose- 
response curve in patients with CHF as compared with 
healthy subjects (right panel of figure). A statistically 
significant difference in the corrected Erna), was found 
(1.57 x 10- ± 8.19 x 10-3 for healthy subjects vs. 
2.10 x 10' ± 7.78 x 10-3 for patients with CHF; 
p < 0.01), but this difference was only 25% and may 
reflect the limited number of individuals studied. The 
corrected baseline response was statistically different 
between groups (1.49 x 10-2 ± 2.19 x 10-3 for 
healthy subjects vs. 3.10 x 10-3 ± 1.24 x 10 -3 for 
patients with CHF; p < 0.001) and, as explained pre- 
viously, may be the result of differences in dietary in- 
take of sodium and in replacement of urinary fluid losses 
between groups. Additionally, there was a two- to three- 
fold increase in the corrected value for ER50 (2.94 x 
10-2 3.73 x 10-3 lig/ ml for healthy subjects vs. 
7.67 x 10-2 ± 1.24 x 10-3 p,g/ ml for patients with 
CHF; p < 0.05). These results may indicate that acute 
diuretic tolerance is occurring in CHF as urinary losses 
were not replaced, or that there may be diuretic resis- 
tance in CHF. If there is an enhancement of proximal 
tubular sodium reabsorption in CHF,'" it would take 
higher urinary concentrations of bumetanide to elicit 
the same response in a patient with CHF as compared 
with a healthy subject. 
When the dose-response parameters of healthy sub- 
jects in our study were compared with healthy subjects 
in a study by Lau et al. ,6 there were no significant 
differences found between E.,R, (2.65 0.24 vs. 
3.82 ± 1.13 mEq/ min, respectively) and the slope 
factor, S (2.01 ± 0.56 vs. 1.61 ± 0.24, respectively). 
However, there were significant differences in both ER50 
(3.46 ± 0.93 vs. 14.0 ± 7.8 lig /min, respectively; 
p < 0.05) and E. (0.252 ± 0.078 vs. 0.085 -± 0.065 
mEq/ min, respectively; p < 0.001). Previous studies 
in animals"'" and man56 have shown that an acute tol- 
erance can develop to furosemide when fluid and elec- 
trolyte replacement is inadequate. More recently, sim- 
ilar results have been confirmed for bumetanide in 
dogs' in which a statistically significant increase of 
ER50 occurred with increasing sodium and fluid deficits 
due to uncompensated urinary losses. These studies 
have demonstrated that when there is inadequate re- 
placement of urinary losses, body mechanisms are rap- 
idly brought into play within a single dose of diuretic 
to conserve body fluids. In the study by Lau et al., 
subjects were kept euvolemic by isovolumetric replace- 
ment of urinary losses, but this was done orally with 
fruit juices. In our study, urinary losses were replaced 
intravenously with lactated Ringer's solution. It may 
be that oral absorption of fluids cannot occur at a rate 
rapid enough to compensate for urinary losses. Con- 
sequently, acute tolerance to bumetanide was evident 
in the study by Lau et al. but not in the present one in 
healthy subjects. 
Ideally, strict and consistent dietary control between 
the treatment groups is preferable. However, because 
we were ethically unable to replace intravenous fluids 
for urine losses in patients with CHF, and because pa- 
tients' diets were adjusted as tolerated by the degree of 
heart failure, it was decided to study each participant 
while he or she was eating his or her normal, stabilized 
diet. Nonetheless, given this clinical necessity, the vari- 
ability in dynamic parameters (Erna,, ER, S) in healthy 
subjects and in patients with CHF was comparable (co- 
efficient of variation, 10% to 40%) with those studies 
in which diet was strictly controlled." Baseline values 
(E.) tend to vary considerably between studies and may 
reflect the hydration status of the individual as well as 
the method of data analysis. 
In conclusion, our results suggest that aside from a 
modest reduction in CLR, the pharmacokinetics of 
bumetanide in patients with CHF are similar to those 
in healthy subjects. The extent of bioavailability of 
3 mg oral doses of bumetanide is approximately 80%, 
with a variability about the mean of 20% to 25% in 
both patients with CHF and healthy volunteers. The 
cumulative pharmacodynamic responses to bumet- 
anide, whether administered orally or intravenously, 
were not significantly different. As a result, it appears 
that with bumetanide the clinician can make a predict- 
able transition from an intravenous 3 mg dose to a 
3 mg oral maintenance dose in patients with CHF. Be- 
cause the two modes of administration provide nearly 
identical respones, the intravenous route should be re- 
served for those patients who require a rapid onset of 
action or in whom oral therapy is not appropriate. 
We thank Michael Nangle and Jill Van Dette for their help 
with the experimental setup and data collection aspects of the 
study. 
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